Biomarkers in Food Allergy Diagnosis

Allergy;Food Clinical Trial

— APSIS  

Official title:

Multi-omics Endotyping of Food-allergic Patients For Advanced Biomarker Discovery

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04604912
• Other study ID #: APSIS
• Status: Completed
• Start date: September 1, 2017
• Est. completion date: December 31, 2023

Study information

• Verified date: March 2024
• Source: Luxembourg Institute of Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Food allergy is a global burden, affecting patients, society as a whole and the economy. For most common food allergies, patients synthesize specific IgE-antibodies against harmless food proteins. Clinical phenotypes of food-allergic patients are highly diverse. Differences in medical symptoms (organs, severity, delay), threshold and cross-reactivity levels suggest variable underlying endotypes. The aim of this study is to identify phenotypic biomarkers for advanced stratification of food-allergic patients. Our study will consist of up to 50 participants (30 food-allergic, 20 tolerant), recruited in Luxembourg. Clinical samples will be collected before, during and after the event of a double-blind placebo-controlled food challenge for patients. Multi-omics analyses of blood (sera, peripheral blood mononuclear cell, basophils) and stool will allow a deeper understanding of the underlying immune mechanisms, including allergen metabolism aspects, as well as the functional gut microbiome. Deciphering these basic aspects during the present pilot study is expected to pave the way towards novel personalized medicine approaches for diagnosing and treating of food-allergic individuals. This study is a cooperation project between the Centre Hospitalier de Luxembourg (CHL), the Luxemburg Institute of Health (LIH), the University of Luxembourg and the Integrated Biobank of Luxemburg (IBBL).

Description:

Background. Food allergies are a global burden causing severe clinical reactions including fatal anaphylaxis. Peanuts are counted among the most potent elicitors involved in IgE-mediated food allergies. Peanut allergy is a relevant disease model because of its steadily increasing prevalence and poor prognosis of outgrowth. Clinical phenotypes of peanut-allergic patients are highly variable. Patients might experience variable medical symptoms (organs, severity, delay), threshold and cross-reactivity levels suggest. Reliable in-vitro biomarker allowing to predict clinical reactivity and score the patients into reaction endotypes are missing. Most important peanut allergens have been studied as to their biomolecular properties biological activities and allergenic potency. The pronounced protein stability of potent peanut allergens is thought to contribute to the molecules' allergenicity. Upon ingestion, food proteins are broken down, entering the human body via epithelial surfaces. The identity and the fate of immunologically active allergen peptides after epithelial absorption remains elusive. Beyond this, complex immune cascades take place during acute allergic episodes. How immune cells, such as lymphocytes, orchestrate in patients with different clinical outcomes (e.g., sensitivity, severity) still remains to be solved. Several studies have shown that the composition and the diversity of the gut microbiota is relevant for shaping the immune response to food proteins. The functional interaction between host and gut microbiome, in the context of symptom development and phenotypic variations, is unexplored until today. Aims. This project aims to explore putative biomarkers at various levels, at the level of IgE-profiles, at the level of allergen absorption, at the level of scored basophil reactivity, at the level of immune phenotypes and at the level of gut microbiome-host interactions, by applying multiple omics technologies. Partners. The Luxembourg Institute of Health (LIH), Department of Infection and Immunity (DII; head Prof. M. Ollert) has the scientific project lead (Principal Investigator Dr. A. Kuehn). Main clinical partners are Dr. F. Codreanu-Morel from the National Unit of Immunology-Allergology, Centre Hospitalier (CHL), Luxembourg, as well as Prof. C. Bindslev-Jensen from Odense Research Centre for Anaphylaxis (ORCA), Denmark. Partner for the execution of the clinical part will be the Clinical and Epidemiological Investigation Center (CIEC, LIH) headed by Dr. M. Gantenbein. The Integrated Biobank of Luxembourg (IBBL) will prepare and store clinical samples until use. Clinical samples (blood, sera, plasma) will be analyzed at DII, LIH. Stool samples will be investigated with the help of Prof. P. Wilmes from the Systems Ecology research group, Luxembourg Centre for Systems Biomedicine (LCSB). Project implementation. Food challenges (OFC) to peanut will be proceeded according to official guidelines (European Academy of Allergy and Clinical Immunology, EAACI). Healthy controls (N=10) will be split, half will receive a single food dose of up to 100 g of roasted peanuts (open OFC) and the other half will be tested with up to 5 incremental doses (double-blind placebo-controlled OFC) using the same doses as for allergic patients. For single-dose OFC, blood samples from controls will be taken before the OFC and at 30 minutes, at 60 minutes and at 120 minutes. Controls receiving 5 incremental allergen doses will be subjected to blood sampling before the beginning of the OFC and 1 h after the end of the challenge. As a further control arm in the study, allergenic food from animal origin will be used in OFC. Further healthy controls (N=10) will receive either a single food dose of up to 200 g of cooked fish (open OFC) and the other half will be tested with up to 5 incremental doses (double-blind placebo-controlled OFC). Doses in a range of 10 mg to 100 g of fish will be selected for the blinded OFC with controls. Allergic participants (N=30) will ingest incremental doses of peanuts. The OFC doses will be in the range of 5 mg, 15 mg, 60 mg, 120 mg, 200 mg, 390 mg, 790 mg, 1,580 mg, 3,160 mg and 5,530 mg of roasted peanut. Maximum five doses will be selected from the above mentioned ranges of peanut doses. Upon observation of allergic symptoms, the OFC will be stopped. If no allergic symptoms occurred during a food challenge with five incremental doses, the patient will be asked to participate in a second oral provocation (min. 14 days later) in order to undergo a test with higher allergen doses. Blood samples from allergic study participants will be drawn prior, during and after OFC (0, 60, 150, 180 minutes). Stool samples from peanut-allergic participants (n=30) and healthy controls (n=20) will be collected earliest 2 months after the food challenge. Prior sampling, participants should not have used antibiotics within the last month, or have recent/ongoing gastrointestinal symptoms (= diarrhea; Bristol scale 5-7) at the time of stool collection. Participants will receive a collection kit at home, containing special sampling tubes, gloves and instructions. In addition, patients are asked to record their food intake for the last 24 hours before sampling. Collected clinical samples will be pseudonymized at the clinical centers. A synonym list, as part of the investigator file, containing the information on the participants' identity and the corresponding pseudonym, will be available at the clinical center only (medical investigators) and at CIEC. Personal data is protected under the regulation (EU) 2016/679 of 27 April 2016 on the protection of individuals with regard to the processing of personal data (GDPR) and the law of 1 August 2018 on the organization of the National Data Protection Commission and the General Data Protection Act.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 74
• Est. completion date: December 31, 2023
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 2 Years to 70 Years

Eligibility

For the allergic cohort :

Inclusion criteria:

• 2-70 years
• male or female
• Allergic to peanut (assessed by anamnesis, skinreactivity testing, sera testing for specific IgE)
• Sign an Informed Consent
• Diagnostic food challenge scheduled

Exclusion criteria:

• Significant co-morbidity
• Medical treatment by nonsteroidal anti-inflammatory drugs oraspirin, chronic treatment with beta-blockers,angiotensin-converting enzyme inhibitors, use ofantihistamines within 5 days of oral food challenge and oral corticosteroids within 14 days prior to the challenge
• Medical unfit for challenge (e.g : fever,unwell with intercurrent illness)
• Pregant women
• Unbalanced asthma
• Severe food-induced anaphylaxis For the control cohort :

Inclusion criteria:

• Adults
• male or female
• Sign an Informed Consent
• Tolerance to peanuts and fish (IgE-titer < 0.10 kUA/L) Exclusion criteria
• Pregnancy
• Medical unfit for challenge (e.g : fever, unwell with intercurrent illness),
• Unbalanced asthma
• Treatment by nonsteroidal anti-inflammatory drugs or aspirin
• Chronic treatment with beta-blockers, angiotensin-converting enzyme inhibitors
• Use of antihistamines within 5 days of oral food challenge
• Oral corticosteroids within 14 days prior to the challenge
• Risk of severe food-induced anaphylaxis in highly sensitized peanut-allergic patients

Related Conditions & MeSH terms

• Allergy;Food
• Food Hypersensitivity
• Hypersensitivity

Locations

Country	Name	City	State
Luxembourg	Luxembourg Institute of Health	Esch-sur-Alzette
Luxembourg	Centre Hospitalier Luxembourg	Luxembourg

Sponsors (6)

Lead Sponsor	Collaborator
Luxembourg Institute of Health	Centre Hospitalier du Luxembourg, Integrated Biobank of Luxembourg, Odense University Hospital, Technical University of Munich, University of Luxembourg

Country where clinical trial is conducted

Luxembourg, 

References & Publications (5)

Bunyavanich S, Berin MC. Food allergy and the microbiome: Current understandings and future directions. J Allergy Clin Immunol. 2019 Dec;144(6):1468-1477. doi: 10.1016/j.jaci.2019.10.019. — View Citation

Costa J, Bavaro SL, Benede S, Diaz-Perales A, Bueno-Diaz C, Gelencser E, Klueber J, Larre C, Lozano-Ojalvo D, Lupi R, Mafra I, Mazzucchelli G, Molina E, Monaci L, Martin-Pedraza L, Piras C, Rodrigues PM, Roncada P, Schrama D, Cirkovic-Velickovic T, Verhoeckx K, Villa C, Kuehn A, Hoffmann-Sommergruber K, Holzhauser T. Are Physicochemical Properties Shaping the Allergenic Potency of Plant Allergens? Clin Rev Allergy Immunol. 2022 Feb;62(1):37-63. doi: 10.1007/s12016-020-08810-9. — View Citation

Jappe U and Kuehn A. Neues zu diagnostisch relevanten Einzelallergenen aus pflanzlichen und tierischen Nahrungsmittelallergenquellen. Allergologie 2016; 39: 425-438. doi: 10.5414/ALX01885.

Matricardi PM, Kleine-Tebbe J, Hoffmann HJ, Valenta R, Hilger C, Hofmaier S, Aalberse RC, Agache I, Asero R, Ballmer-Weber B, Barber D, Beyer K, Biedermann T, Bilo MB, Blank S, Bohle B, Bosshard PP, Breiteneder H, Brough HA, Caraballo L, Caubet JC, Crameri R, Davies JM, Douladiris N, Ebisawa M, EIgenmann PA, Fernandez-Rivas M, Ferreira F, Gadermaier G, Glatz M, Hamilton RG, Hawranek T, Hellings P, Hoffmann-Sommergruber K, Jakob T, Jappe U, Jutel M, Kamath SD, Knol EF, Korosec P, Kuehn A, Lack G, Lopata AL, Makela M, Morisset M, Niederberger V, Nowak-Wegrzyn AH, Papadopoulos NG, Pastorello EA, Pauli G, Platts-Mills T, Posa D, Poulsen LK, Raulf M, Sastre J, Scala E, Schmid JM, Schmid-Grendelmeier P, van Hage M, van Ree R, Vieths S, Weber R, Wickman M, Muraro A, Ollert M. EAACI Molecular Allergology User's Guide. Pediatr Allergy Immunol. 2016 May;27 Suppl 23:1-250. doi: 10.1111/pai.12563. — View Citation

Muraro A, Lemanske RF Jr, Castells M, Torres MJ, Khan D, Simon HU, Bindslev-Jensen C, Burks W, Poulsen LK, Sampson HA, Worm M, Nadeau KC. Precision medicine in allergic disease-food allergy, drug allergy, and anaphylaxis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology. Allergy. 2017 Jul;72(7):1006-1021. doi: 10.1111/all.13132. Epub 2017 Apr 12. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in peripheral allergen peptides (serum samples) across food allergen uptake	Abundance of allergen peptides as detected through mass spectrometry. Main comparison will be on two study arms, food-allergic patients versus healthy controls	Samples analyzed through study completion, an average of 3 months
Primary	Change in in-vitro basophil reactivity profiles (cells sampled before food challenge) using defined food allergen peptides across different peptides mixes and peptide concentrations	Reactivity of effector cells by dose-dependent activation (%-CD63+ CCR3+basophils) and flow cytometry measurement. Main comparison will be within the group of food-allergic patients, aligning patients with high/low reactivity and high/low sensitivity of basophils.	Samples analyzed through study completion, an average of 3 months
Primary	Change of immune cell phenotypes across food allergen uptake	Abundance and function of immune cells as detected through single-cell mass cytometry. Main comparison will be on two study arms, food-allergic patients versus healthy controls.	Samples analyzed through study completion, an average of 3 months
Primary	Change in Cytokine release	Cytokine quantification through multiplex immunoassays. Main comparison will be on two study arms, food-allergic patients versus healthy controls.	Samples analyzed through study completion, an average of 3 months
Primary	Baseline characteristics of the functional gut microbiome in food-allergic patients	DNA, RNA, protein and metabolite profiling using a multi-omics approach through 16S RNA sequencing, unbiased high resolution method of metagenomics shotgun sequencing and transcriptomic analysis (Illumina MiSeq & NextSeq) as well as metabolomic analysis (gas chromatography-mass spectrometry/liquid chromatography-mass spectrometry). In addition, microbial component analysis by antibody-specific immunoassays and flow cytometry. Main comparison will be on two study arms, food-allergic patients versus healthy controls.	Samples analyzed through study completion, an average of 2 months